Depression – Cybin 003-002

Feb 23

About the Study

For adults with a diagnosis of Major Depressive Disorder (MDD) currently experiencing a Major Depressive Episode (MDE).

The goal of this study is to evaluate the efficacy, safety, and tolerability of CYB003, compared to placebo, in treating symptoms of MDD in adult participants.

This study is sponsored by Cybin.

Eligibility

You may be eligible to participate in this study if you:

are between the ages of 18-85 years old
meet DSM-5 criteria for Major Depressive Disorder (MDD) diagnosis
are currently on a stable dose of anti-depressant medication for at least 4 weeks, with inadequate response
are able to remain in our private suite for the entire dosing session (up to 8 hours) for each dosing day

If you are interested in participating in this clinical trial, please call our friendly staff at 801-871-5516 today. You can also fill out the contact form below.

View our Privacy Policy

Condition: Depression

Jamie Robison

Depression – Cybin 003-002

About the Study

Eligibility

Clinical trials advance medicine for the benefit of communities everywhere.
Inner Space Research provides patients access to emerging therapies and generates the rigorous data regulatory agencies need to evaluate their safety and efficacy.

Inner Space Research LLC

Depression – Cybin 003-002

About the Study

Eligibility

Depression – J&J MDD3014

Clinical trials advance medicine for the benefit of communities everywhere.Inner Space Research provides patients access to emerging therapies and generates the rigorous data regulatory agencies need to evaluate their safety and efficacy.

Inner Space Research LLC

Clinical trials advance medicine for the benefit of communities everywhere.
Inner Space Research provides patients access to emerging therapies and generates the rigorous data regulatory agencies need to evaluate their safety and efficacy.